Fusen Pharmaceutical Past Earnings Performance
Past criteria checks 0/6
Fusen Pharmaceutical's earnings have been declining at an average annual rate of -63.6%, while the Pharmaceuticals industry saw earnings growing at 5.7% annually. Revenues have been growing at an average rate of 5.7% per year.
Key information
-63.6%
Earnings growth rate
-63.6%
EPS growth rate
| Pharmaceuticals Industry Growth | 5.6% |
| Revenue growth rate | 5.7% |
| Return on equity | -17.3% |
| Net Margin | -21.1% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Fusen Pharmaceutical (HKG:1652) Use Of Debt Could Be Considered Risky
May 21
Fusen Pharmaceutical Company Limited's (HKG:1652) Popularity With Investors Under Threat As Stock Sinks 27%
Mar 31Fusen Pharmaceutical (HKG:1652) Use Of Debt Could Be Considered Risky
Dec 14Here's Why Fusen Pharmaceutical (HKG:1652) Can Manage Its Debt Responsibly
Sep 02Fusen Pharmaceutical (HKG:1652) Seems To Use Debt Quite Sensibly
Apr 02A Look At Fusen Pharmaceutical's (HKG:1652) Share Price Returns
Mar 06We Wouldn't Rely On Fusen Pharmaceutical's (HKG:1652) Statutory Earnings As A Guide
Feb 08
Is Fusen Pharmaceutical Company Limited's (HKG:1652) Recent Price Movement Underpinned By Its Weak Fundamentals?
Jan 18Does Fusen Pharmaceutical (HKG:1652) Have A Healthy Balance Sheet?
Dec 28What You Need To Know About Fusen Pharmaceutical Company Limited's (HKG:1652) Investor Composition
Dec 07If You Had Bought Fusen Pharmaceutical (HKG:1652) Shares A Year Ago You'd Have Earned 34% Returns
Nov 20Revenue & Expenses Breakdown
How Fusen Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 425 | -90 | 188 | 98 |
| 31 Mar 24 | 496 | -63 | 201 | 82 |
| 31 Dec 23 | 566 | -36 | 214 | 65 |
| 30 Sep 23 | 614 | -24 | 227 | 40 |
| 30 Jun 23 | 663 | -11 | 216 | 39 |
| 31 Mar 23 | 577 | -23 | 195 | 27 |
| 31 Dec 22 | 492 | -35 | 173 | 15 |
| 30 Sep 22 | 414 | -34 | 160 | 8 |
| 30 Jun 22 | 337 | -34 | 146 | 0 |
| 31 Mar 22 | 361 | -9 | 151 | 0 |
| 31 Dec 21 | 386 | 17 | 156 | 0 |
| 30 Sep 21 | 420 | 48 | 160 | 0 |
| 30 Jun 21 | 454 | 79 | 165 | 0 |
| 31 Mar 21 | 470 | 75 | 175 | 0 |
| 31 Dec 20 | 487 | 70 | 186 | 0 |
| 30 Sep 20 | 473 | 67 | 190 | 0 |
| 30 Jun 20 | 458 | 65 | 193 | 0 |
| 31 Mar 20 | 433 | 59 | 182 | 0 |
| 31 Dec 19 | 407 | 53 | 172 | 0 |
| 30 Sep 19 | 397 | 63 | 154 | 0 |
| 30 Jun 19 | 387 | 72 | 137 | 0 |
| 31 Mar 19 | 424 | 87 | 138 | 0 |
| 31 Dec 18 | 462 | 102 | 139 | 0 |
| 30 Sep 18 | 507 | 102 | 158 | 0 |
| 30 Jun 18 | 493 | 98 | 156 | 0 |
| 31 Mar 18 | 473 | 98 | 146 | 0 |
| 31 Dec 17 | 453 | 97 | 136 | 0 |
| 30 Sep 17 | 427 | 86 | 127 | 0 |
| 31 Dec 16 | 442 | 95 | 112 | 0 |
| 31 Dec 15 | 369 | 45 | 86 | 0 |
Quality Earnings: 1652 is currently unprofitable.
Growing Profit Margin: 1652 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 1652 is unprofitable, and losses have increased over the past 5 years at a rate of 63.6% per year.
Accelerating Growth: Unable to compare 1652's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 1652 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (6.4%).
Return on Equity
High ROE: 1652 has a negative Return on Equity (-17.28%), as it is currently unprofitable.